The past few years have exposed the deep vulnerabilities of our global pharmaceutical supply chains.
Our heavy dependence on active pharmaceutical ingredient (API) production amplifies this challenge as regional disruptions can trigger widespread ripple effects throughout global healthcare systems.
Drug shortages also result from problems at large centralised manufacturing sites.
A 2023 survey revealed that more than 99% of hospital and health system pharmacists experience drug shortages, with 85% describing the severity as critically or moderately impactful.1
Moreover, millions of people in low- and middle-income countries continue to struggle with inadequate access to essential medicines, subsequently widening health disparities and limiting treatment options for patients in need.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
